Firm B Capital Has Allocated $500 Million To Launch A New Fund That Hunts For Opportunities In The Healthcare Sector


US- grounded adventure capital  establishment B Capital Group, which has backed Indian startups like Byju’s, Meesho and BlackBuck, on Thursday said it has marked the final close of its first healthcare fund. The fund, closed at$ 500 million, will invest in the healthcare sector, ranging from biotech to digital health. “ Technological advancements in biology, AI, and  robotization are transubstantiation of the assiduity, with business models seeing the confluence of traditional players in  new ways.

This moment presents a unique  occasion for B Capital to work our devoted healthcare capital and active investment strategy to find and support companies advancing the healthcare sector, ” said, Robert Mittendorff, MD, general mate and head of healthcare at B Capital. Innovated in 2015 by Eduardo Saverin and Raj Ganguly, B Capital focuses on late-stage startups working in the enterprise, fiscal technology and healthcare sectors. It manages nearly $6.3 Bn worth of means under operation (AUM). B Capital operates nine services across the US and Asia. It also has a strategic  cooperation with BCG to support startups to gauge and expand into new  requests.

Morgan said B Capital’s approach to global adventure and growth investment, including its cooperation with Boston Consulting Group (BCG), places authors and operation brigades frontal-and-centre and surrounds them with coffers they need to transfigure large requests. B Capital in India is presently invested in companies similar as B2B seller digitisation platform for brands and enterprises Bizongo, online trucking platform BlackBuck, social commerce incipiency Meesho, edtech major Byju’s, and online drugstore incipiency Pharmeasy. The investment establishment’s healthcare portfolio includes further than 20 early and late- stage startups grounded in the US, Asia and Europe. Its portfolio spans across healthtech, digital health, biotech and medtech parts.

Of late, it led investment rounds in Hotspot rectifiers, Triumvira, CapitalRX and Carlsmed. As per B Capital, in January 2023, it closed its Growth Fund III and combined finances with aggregate capital commitments of about $2.1 Bn.